Public-registry site landscape for NCT07721025, a Friedreich Ataxia study sponsored by Lexeo Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07721025 (registry record) |
| Sponsor | Lexeo Therapeutics |
| Condition(s) | Friedreich Ataxia; Cardiomyopathy, Secondary |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
At University of South Florida — one of the facilities listed on this trial — 3 other studies are actively recruiting Friedreich Ataxia patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07721025 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →